Minerva Neurosciences (NERV) Enterprise Value (2014 - 2026)

Minerva Neurosciences (NERV) has 14 years of Enterprise Value data on file, last reported at -$32.8 million in Q1 2026.

• Quarterly Enterprise Value fell 88.38% year-over-year to -$32.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$32.8 million (down 88.38% YoY) and the FY2025 annual result came in at -$82.4 million, down 283.94% from the prior year.
• Enterprise Value climbed to -$32.8 million in Q1 2026, from -$82.4 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$12.4 million in Q3 2025 to a low of -$82.4 million in Q4 2025.
• A 5-year average of -$36.3 million and a median of -$34.7 million in 2022 frame the typical range for Enterprise Value.
• The widest YoY moves for Enterprise Value: up 53.48% in 2025, down 283.94% in 2025.
• Tracing NERV's Enterprise Value over 5 years: stood at -$34.7 million in 2022, then increased by 20.79% to -$27.5 million in 2023, then rose by 21.82% to -$21.5 million in 2024, then plunged by 283.94% to -$82.4 million in 2025, then surged by 60.24% to -$32.8 million in 2026.
• The last three Enterprise Value figures came in at -$32.8 million (Q1 2026), -$82.4 million (Q4 2025), and -$12.4 million (Q3 2025), per Business Quant data.